A5004006706- Diabetes Management and Research
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Global Health Care Issues
- Pharmaceutical Economics and Policy
- COVID-19 epidemiological studies
- Diabetes and associated disorders
- Pharmaceutical industry and healthcare
- Heparin-Induced Thrombocytopenia and Thrombosis
- Autoimmune Bullous Skin Diseases
- Blood Pressure and Hypertension Studies
- Drug-Induced Adverse Reactions
- COVID-19 Pandemic Impacts
- Delphi Technique in Research
- Innovation Policy and R&D
- Metabolism, Diabetes, and Cancer
- COVID-19 and healthcare impacts
- Genomics and Rare Diseases
- Quality and Safety in Healthcare
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Diabetes, Cardiovascular Risks, and Lipoproteins
Medical University of Warsaw
2020-2024
Complications contribute largely to the economic gravity of diabetes mellitus (DM). How they arise and are treated differs substantially between countries. This paper assesses total annual, direct, indirect cost severe hypoglycemia events (SHEs) in nine European countries: Bulgaria, Croatia, Czech Republic, Greece, Hungary, Macedonia/the former Yugoslav Republic Macedonia (MK), Poland, Slovenia, Spain.Data was collected on epidemiology, treatment structure, SHE-driven resource consumption,...
Abstract Our objective was to compare AOTMiT (Polish: Agencja Oceny Technologii Medycznych i Taryfikacji) recommendations other HTA (Health Technology Assessment) agencies for newly registered drugs and new registration indications issued by the European Medicines Agency between 2014 2019. The study aims assess consistency justifications of compared that in 11 countries. A total 2494 reimbursement published 12 464 medicinal products 525 were analyzed. analysis confirmed Polish agency seems...
Background: The cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it become essential to accurately estimate the overall societal costs of, both direct indirect from points of view including patients, caregivers employers. Research design: This paper aims measure cost diseases, in Poland for 2015-2017. Direct related treatment calculated based data available domain. We use a modified human capital...
In January 2017, a new funding model for diagnostic genetic testing in cancer was introduced Poland.The aim of this study to assess the impact changing diagnosis oncology on improving access personalized medicine Poland between 2017 and 2019.The analysis included data settlements with National Health Fund tests under contract hospital treatment type separately contracted services 150,647 were reported, which billed 111,872 patients. The average number per patient 1.35. One test 83.5%...
Background To analyze the time from drug registration to reimbursement recommendations, we examined medicinal products, including new clinical indications, registered by EMA between 2014 and 2019 across various therapeutic areas.
Introduction. The novel emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global public health concern. ongoing pandemic outbreak in Poland makes great impact on the diagnosis and treatment of other conditions including cancer non-neoplastic diseases such as diseases. Research design. This study aimed to analyze trends morbidity selected over last 6 years assess SARS-CoV-2 (COVID-19) incidence from January 1, 2020, December 31, compared...